Drug Trial Radar · NCT05108025
DMT310-005 Topical in the Treatment of Acne Rosacea
Last checked: Nov 19, 2026Latest source record: Dec 8, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
180
Actual
Start
Nov 15, 2021
Primary completion
Dec 2022
Study completion Dec 2022
Sponsor
- Lead sponsor
- Dermata TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Nov 4, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder mixed with diluent in male and female patients with moderate to severe facial acne rosacea.
Conditions
- Acne Rosacea
Interventions
Topical PowderDrug
Topical Powder mixed with diluent
Placebo Topical PowderDrug
Placebo Topical Powder mixed with diluent
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy as measured by lesion countsTime frame: 12 Weeks
- Efficacy as measured by Investigator Global Assessment (IGA)Time frame: 12 Weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Dermata Investigational Site
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.